Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

POZEN presents PA32540 Phase 1 study results for cardiovascular disease at AHA Session

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today the results of a Phase 1 study, which reported that PA32540, a novel coordinated-delivery tablet of enteric-coated aspirin (325 mg) and immediate-release omeprazole (40 mg), showed no ex vivo drug-drug interaction with clopidogrel when administered 10 hours apart in healthy patients, based on the study's pre-specified analysis.

15 Nov 2010

Acute sleep deprivation increases inflammation: Research

People who sleep poorly or do not get enough sleep have higher levels of inflammation, a risk factor for heart disease and stroke, researchers have found.

15 Nov 2010

Job strain can increase risk of cardiovascular disease in women

Women who report having high job strain have a 40 percent increased risk of cardiovascular disease, including heart attacks and the need for procedures to open blocked arteries, compared to those with low job strain, according to research presented at the American Heart Association's Scientific Sessions 2010.

14 Nov 2010

Nile third quarter net loss decreases to $1.8 million

Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for therapeutics for cardiovascular disease, today announced its third quarter financial results for 2010.

12 Nov 2010

VIMOVO granted marketing and pricing approval in the UK

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it has been notified by AstraZeneca that marketing and pricing approval for VIMOVO™ (naproxen/ esomeprazole magnesium) 500/20 mg modified-release tablets, has been granted in the United Kingdom (UK).

12 Nov 2010

Scientists unveil mechanism of liver regeneration

The liver's unique ability among organs to regenerate itself has been little understood. Now Weill Cornell Medical College scientists have shed light on how the liver restores itself by demonstrating that endothelial cells the cells that form the lining of blood vessels play a key role.

12 Nov 2010

Lancet series focuses on chronic diseases, development

"Just a small percentage of low- and middle-income countries' health care budgets are allocated toward the treatment and prevention of chronic diseases even though such illnesses are expected to account for 69% of global deaths by 2030," according to a paper published Wednesday in the Lancet, as part of a series on chronic disease and development, ModernHealthcare.com reports.

12 Nov 2010

Bristol-Myers Squibb announces first large-scale diabetes initiative to develop self-management program

The Bristol-Myers Squibb Foundation today announced Together on Diabetes: Communities Uniting to Meet America's Diabetes Challenge, a 5-year, $100 million initiative to help patients living with type 2 diabetes better manage their disease beyond the doors of their doctor's office in their homes and communities and for the course of their disease.

12 Nov 2010

Hospital for Special Surgery presents advantages of specialized disease center for comprehensive lupus care

The benefits of collaborative, multidisciplinary care of patients with complex autoimmune diseases like lupus and multiple sclerosis are just beginning to be appreciated by physicians. Hospital for Special Surgery in New York will present evidence of the advantages of such a specialized disease center dedicated to comprehensive lupus care at the 74th Annual Meeting of the American College of Rheumatology in Atlanta.

11 Nov 2010

Study: Cognitive symptoms of depression cannot be discarded as risk factors for heart disease progression

Cognitive symptoms of depression cannot be simply discarded as risk factors for heart disease progression. When using a structured diagnostic interview, both somatic and cognitive symptoms of depression are associated with adverse cardiac outcome after adjusting for potential confounders.

11 Nov 2010

Resistance exercise may promote better cardiovascular health

Resistance exercise (such as lifting weights) produces a different pattern of blood vessel responses than aerobic exercise, suggesting that it may have specific and important benefits for cardiovascular health, according to a study in the November issue of The Journal of Strength and Conditioning Research, official research journal of the National Strength and Conditioning Association.

11 Nov 2010

ESC emphasizes simple measures for diabetic patients to slow-down CVD progression

Diabetics can face a five times increase in the risk of developing cardiovascular disease (CVD) than non-diabetics. This leads to a seven to ten year reduction in life expectancy and a higher probability of suffering a fatal heart attack. These sad statistics have prompted the European Society of Cardiology (ESC) to mark World Diabetes Day on 14 November 2010 by emphasising the simple measures that diabetes patients should adopt to slow-down the progression of CVD and greatly improve their quality of life.

11 Nov 2010

Mother's poor nutrition during pregnancy affects offspring's ability to process medications

New research has found that a mother's poor nutrition during pregnancy and nursing can cause problems for her offspring's ability to process medications, even well into adulthood.

11 Nov 2010

Egrifta receives FDA approval for treatment of HIV-lipodystrophy

The U.S. Food and Drug Administration today approved Egrifta (tesamorelin) to treat HIV patients with lipodystrophy, a condition in which excess fat develops in different areas of the body, most notably around the liver, stomach, and other abdominal organs. The condition is associated with many antiretroviral drugs used to treat HIV.

10 Nov 2010

Amarin reports $31.4 million cash balance for third quarter 2010

Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on cardiovascular disease, today reported its financial and operational results for the three-month period ended September 30, 2010.

10 Nov 2010

Statins benefit ‘at risk’ patients but are underused: Study

A look at some of the large clinical trials and studies has shown that thousands of deaths could be prevented a year if people at risk of heart attack or stroke are prescribed high doses of statins. The review involves data from 170,000 patients in 26 randomized trials. The paper is published in the journal The Lancet.

10 Nov 2010

Obese teens become obese adults

A new report shows that obese adolescent Americans tend to carry their extra weight into adulthood. The nationally representative study of American youth showed that one in 12 teenagers became severely obese as they entered adulthood with some 100 pounds above their ideal weight. And nearly half the girls and more than a third of the boys who are obese as teenagers grew up to be obese adults with a high risk of developing heart disease, diabetes and certain types of cancers.

10 Nov 2010

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced additional positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines.

10 Nov 2010

PPIs, antiplatelet drugs can help treat CV disease patients at high risk of upper GI bleeding

Using proton pump inhibitors and antiplatelet drugs (thienopyridines) together is an appropriate way of treating patients with cardiovascular disease who are at high risk of upper gastrointestinal bleeds, despite recent concerns about an adverse interaction between these two types of drugs, according to an Expert Consensus Document released jointly today by the American College of Cardiology Foundation, the American College of Gastroenterology, and the American Heart Association.

10 Nov 2010

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that a compound identified by the Company as an antagonist of GPR87, an orphan GPCR recently unlocked for drug development by Omeros and linked to squamous cell carcinoma, potentiates the tumor-killing activity of doxorubicin (Adriamycin), a widely used chemotherapeutic agent.

10 Nov 2010

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

POZEN presents PA32540 Phase 1 study results for cardiovascular disease at AHA Session

Acute sleep deprivation increases inflammation: Research

Job strain can increase risk of cardiovascular disease in women

Nile third quarter net loss decreases to $1.8 million

VIMOVO granted marketing and pricing approval in the UK

Scientists unveil mechanism of liver regeneration

Lancet series focuses on chronic diseases, development

Bristol-Myers Squibb announces first large-scale diabetes initiative to develop self-management program

Hospital for Special Surgery presents advantages of specialized disease center for comprehensive lupus care

Study: Cognitive symptoms of depression cannot be discarded as risk factors for heart disease progression

Resistance exercise may promote better cardiovascular health

ESC emphasizes simple measures for diabetic patients to slow-down CVD progression

Mother's poor nutrition during pregnancy affects offspring's ability to process medications

Egrifta receives FDA approval for treatment of HIV-lipodystrophy

Amarin reports $31.4 million cash balance for third quarter 2010

Statins benefit ‘at risk’ patients but are underused: Study

Obese teens become obese adults

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

PPIs, antiplatelet drugs can help treat CV disease patients at high risk of upper GI bleeding

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in